Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 257.15 KB
Add to list
  1. Search results
  2. European guidelines on managing adver...

European guidelines on managing adverse effects of medication for ADHD

J Graham, T Banaschewski, J Buitelaar, D Coghill, M Danckaerts, RW Dittmann, M Doepfner, R Hamilton, C Hollis, M Holtmann, et al.
(2011) EUROPEAN CHILD & ADOLESCENT PSYCHIATRY. 20(1). p.17-37
Author
Organization
Abstract
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
Keywords
YOUNG-ADULTS, OF-THE-LITERATURE, ADHD, HKS, Medication, Adverse, Guidelines, European, Children, PROSPECTIVE FOLLOW-UP, SUDDEN CARDIAC DEATH, RANDOMIZED CONTROLLED-TRIAL, COMORBID TIC DISORDERS, PEDIATRIC BURN INJURY, ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER, DEFICIT-HYPERACTIVITY DISORDER, SUBSTANCE USE DISORDERS

Downloads

  • Download
    Graham Banaschewski2011 ECAP.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 257.15 KB

Citation

Please use this url to cite or link to this publication:

MLA
Graham, J., et al. “European Guidelines on Managing Adverse Effects of Medication for ADHD.” EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, vol. 20, no. 1, 2011, pp. 17–37, doi:10.1007/s00787-010-0140-6.
APA
Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R., … Taylor, E. (2011). European guidelines on managing adverse effects of medication for ADHD. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 20(1), 17–37. https://doi.org/10.1007/s00787-010-0140-6
Chicago author-date
Graham, J, T Banaschewski, J Buitelaar, D Coghill, M Danckaerts, RW Dittmann, M Doepfner, et al. 2011. “European Guidelines on Managing Adverse Effects of Medication for ADHD.” EUROPEAN CHILD & ADOLESCENT PSYCHIATRY 20 (1): 17–37. https://doi.org/10.1007/s00787-010-0140-6.
Chicago author-date (all authors)
Graham, J, T Banaschewski, J Buitelaar, D Coghill, M Danckaerts, RW Dittmann, M Doepfner, R Hamilton, C Hollis, M Holtmann, M Hulpke-Wette, M Lecendreux, E Rosenthal, A Rothenberger, P Santosh, J Sergeant, E Simonoff, Edmund Barke, ICK Wong, A Zuddas, HC Steinhausen, and E Taylor. 2011. “European Guidelines on Managing Adverse Effects of Medication for ADHD.” EUROPEAN CHILD & ADOLESCENT PSYCHIATRY 20 (1): 17–37. doi:10.1007/s00787-010-0140-6.
Vancouver
1.
Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann R, et al. European guidelines on managing adverse effects of medication for ADHD. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY. 2011;20(1):17–37.
IEEE
[1]
J. Graham et al., “European guidelines on managing adverse effects of medication for ADHD,” EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, vol. 20, no. 1, pp. 17–37, 2011.
@article{1847634,
  abstract     = {{The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.}},
  author       = {{Graham, J and Banaschewski, T and Buitelaar, J and Coghill, D and Danckaerts, M and Dittmann, RW and Doepfner, M and Hamilton, R and Hollis, C and Holtmann, M and Hulpke-Wette, M and Lecendreux, M and Rosenthal, E and Rothenberger, A and Santosh, P and Sergeant, J and Simonoff, E and Barke, Edmund and Wong, ICK and Zuddas, A and Steinhausen, HC and Taylor, E}},
  issn         = {{1018-8827}},
  journal      = {{EUROPEAN CHILD & ADOLESCENT PSYCHIATRY}},
  keywords     = {{YOUNG-ADULTS,OF-THE-LITERATURE,ADHD,HKS,Medication,Adverse,Guidelines,European,Children,PROSPECTIVE FOLLOW-UP,SUDDEN CARDIAC DEATH,RANDOMIZED CONTROLLED-TRIAL,COMORBID TIC DISORDERS,PEDIATRIC BURN INJURY,ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER,DEFICIT-HYPERACTIVITY DISORDER,SUBSTANCE USE DISORDERS}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{17--37}},
  title        = {{European guidelines on managing adverse effects of medication for ADHD}},
  url          = {{http://doi.org/10.1007/s00787-010-0140-6}},
  volume       = {{20}},
  year         = {{2011}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: